BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 26227487)

  • 1. Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach.
    Ning Y; Hanna DL; Zhang W; Mendez A; Yang D; El-Khoueiry R; Matsusaka S; Sunakawa Y; Stremitzer S; Parekh A; Okazaki S; Berger MD; Barzi A; Lenz HJ
    Mol Cancer Ther; 2015 Oct; 14(10):2401-8. PubMed ID: 26227487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients.
    Ning Y; Zhang W; Hanna DL; Yang D; Okazaki S; Berger MD; Miyamoto Y; Suenaga M; Schirripa M; El-Khoueiry A; Lenz HJ
    Pharmacogenomics J; 2018 Jan; 18(1):29-34. PubMed ID: 27503579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of circulating tumor cells with CK20 RT-PCR is an independent negative prognostic marker in colon cancer patients - a prospective study.
    Hinz S; Hendricks A; Wittig A; Schafmayer C; Tepel J; Kalthoff H; Becker T; Röder C
    BMC Cancer; 2017 Jan; 17(1):53. PubMed ID: 28086834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer.
    Barbazán J; Muinelo-Romay L; Vieito M; Candamio S; Díaz-López A; Cano A; Gómez-Tato A; Casares de Cal Mde L; Abal M; López-López R
    Int J Cancer; 2014 Dec; 135(11):2633-43. PubMed ID: 24752533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of CTCs and CSCs of tumor drainage vein blood in Dukes' stage B and C colorectal cancer patients.
    Shimada R; Iinuma H; Akahane T; Horiuchi A; Watanabe T
    Oncol Rep; 2012 Apr; 27(4):947-53. PubMed ID: 22267181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative real-time RT-PCR detection for survivin, CK20 and CEA in peripheral blood of colorectal cancer patients.
    Shen C; Hu L; Xia L; Li Y
    Jpn J Clin Oncol; 2008 Nov; 38(11):770-6. PubMed ID: 18845519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of cytokeratin 20 mRNA in the peripheral blood of patients with colorectal cancer by immunomagnetic bead enrichment and real-time reverse transcriptase-polymeras chain reaction.
    Guo J; Xiao B; Jin Z; Qin L; Chen J; Chen H; Zhang X; Liu Z
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1279-84. PubMed ID: 16048578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneous detection of circulating tumor cells in patients with colorectal cancer by immunomagnetic enrichment using different EpCAM-specific antibodies.
    Antolovic D; Galindo L; Carstens A; Rahbari N; Büchler MW; Weitz J; Koch M
    BMC Biotechnol; 2010 Apr; 10():35. PubMed ID: 20426872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients.
    Mostert B; Sieuwerts AM; Bolt-de Vries J; Kraan J; Lalmahomed Z; van Galen A; van der Spoel P; de Weerd V; Ramírez-Moreno R; Smid M; Verhoef C; IJzermans JN; Gratama JW; Sleijfer S; Foekens JA; Martens JW
    Mol Oncol; 2015 Apr; 9(4):920-32. PubMed ID: 25655581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients.
    de Albuquerque A; Kubisch I; Stölzel U; Ernst D; Boese-Landgraf J; Breier G; Stamminger G; Fersis N; Kaul S
    J Transl Med; 2012 Nov; 10():222. PubMed ID: 23146106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular markers in circulating tumour cells from metastatic colorectal cancer patients.
    Gazzaniga P; Gradilone A; Petracca A; Nicolazzo C; Raimondi C; Iacovelli R; Naso G; Cortesi E
    J Cell Mol Med; 2010 Aug; 14(8):2073-7. PubMed ID: 20597995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of cytokeratin 20-positive circulating tumor cells detected by a refined immunomagnetic enrichment assay in colorectal cancer patients.
    Wong SC; Chan CM; Ma BB; Hui EP; Ng SS; Lai PB; Cheung MT; Lo ES; Chan AK; Lam MY; Au TC; Chan AT
    Clin Cancer Res; 2009 Feb; 15(3):1005-12. PubMed ID: 19188172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and clinicopathological significance of circulating tumor cells detected by RT-PCR in non-metastatic colorectal cancer: a meta-analysis and systematic review.
    Yang C; Zou K; Zheng L; Xiong B
    BMC Cancer; 2017 Nov; 17(1):725. PubMed ID: 29115932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
    Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
    J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab.
    Musella V; Pietrantonio F; Di Buduo E; Iacovelli R; Martinetti A; Sottotetti E; Bossi I; Maggi C; Di Bartolomeo M; de Braud F; Daidone MG; Cappelletti V
    Int J Cancer; 2015 Sep; 137(6):1467-74. PubMed ID: 25704501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiling of single circulating tumor cells in ovarian cancer - Establishment of a multi-marker gene panel.
    Blassl C; Kuhlmann JD; Webers A; Wimberger P; Fehm T; Neubauer H
    Mol Oncol; 2016 Aug; 10(7):1030-42. PubMed ID: 27157930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
    Sastre J; Vidaurreta M; Gómez A; Rivera F; Massutí B; López MR; Abad A; Gallen M; Benavides M; Aranda E; Rubio ED;
    Clin Colorectal Cancer; 2013 Dec; 12(4):280-6. PubMed ID: 24012456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor cell levels are elevated in colorectal cancer patients with high tumor burden in the liver.
    Kaifi JT; Kunkel M; Dicker DT; Joude J; Allen JE; Das A; Zhu J; Yang Z; Sarwani NE; Li G; Staveley-O'Carroll KF; El-Deiry WS
    Cancer Biol Ther; 2015; 16(5):690-8. PubMed ID: 25785486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of carcinoembryonic antigen-, cytokeratin 19-, or survivin-positive circulating tumor cells in the peripheral blood of esophageal squamous cell carcinoma patients treated with radiotherapy.
    Yin XD; Yuan X; Xue JJ; Wang R; Zhang ZR; Tong JD
    Dis Esophagus; 2012; 25(8):750-6. PubMed ID: 22394149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.